Detalles de la búsqueda
1.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Mult Scler
; 28(14): 2263-2273, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131595
2.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med
; 373(15): 1418-28, 2015 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26444729
3.
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Mult Scler
; 24(6): 795-804, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28485186
4.
In vivo maintenance of human regulatory T cells during CD25 blockade.
J Immunol
; 194(1): 84-92, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25416807
5.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Lancet
; 381(9884): 2167-75, 2013 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23562009
6.
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Mult Scler
; 17(12): 1441-8, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21807759
7.
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Clin Transl Immunology
; 10(6): e1295, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34141433
8.
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.
Mult Scler Relat Disord
; 39: 101865, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31835206
9.
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Mult Scler J Exp Transl Clin
; 6(2): 2055217320918619, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32440353
10.
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Mult Scler Relat Disord
; 27: 101-111, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30368221
11.
Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
Clin Ther
; 40(12): 2021-2030.e1, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30447891
12.
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 11: 18-24, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28104250
13.
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 17: 32-40, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29055471
14.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
J Neurol
; 261(2): 316-23, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24375015
15.
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.
Mult Scler
; 11(5): 568-72, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16193895
16.
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Mult Scler
; 11(4): 409-19, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16042223
Resultados
1 -
16
de 16
1
Próxima >
>>